The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.

The study showed that these vectors have the potential to improve delivery of medication to the eye. It’s a good demonstration of the technology’s potential, building further on our two recent major licensing agreements, with Novo Nordisk and Ionis Pharmaceuticals.

With thanks to Stephane Girard, PhD, Ophthalmology Department Manager, and Sebastien Roux, PhD, Neuroscientist, for their work on this.